Skip to main content

Impact of chemerin, lipid profile, and insulin resistance on disease parameters in patients with multiple sclerosis

Neurological Sciences volume 42, pages 2471–2479 (2021)Cite this article

Abstract

Introduction

Plasma chemerin, which has chemotactic and adipogenic functions, is increased in several inflammatory diseases. However, its relationship with multiple sclerosis (MS) has not been explored yet. In this study, we aimed to determine chemerin levels and their possible role in MS.

Methods

Chemerin serum concentrations were evaluated by using ELISA kit in 91 clinically definite MS patients and 52 healthy controls. The mean serum chemerin, insulin, and cholesterol levels were compared. Patients were divided into two groups according to the body mass index (BMI), and the relationships between clinical and metabolic parameters were evaluated.

Results

Serum chemerin levels were 10.46 ± 1.65 ng/mL in MS patients and 10.26 ± 2.14 ng/mL in the control group. No significant difference was found between patients and controls (p = 0.55). We found no difference regarding age, gender, and BMI between two groups (p = 0.053, p = 0.54, p = 0.41). However, female patients with MS had higher chemerin levels than male patients. There were no associations between serum chemerin levels and EDSS score, annualized relapse rate, BMI, insulin resistance, and serum cholesterol levels in MS patients.

Conclusion

In this study, we aimed to determine serum chemerin levels in patients with MS. However, in our study, there was no significant difference between serum chemerin levels of MS patients and healthy controls’. Additionally, chemerin levels were not associated with other metabolic parameters, as well as cognitive dysfunction. Further studies are needed to evaluate the role of chemerin in MS patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Amato MP, Derfuss T, Hemmer B, Liblau R, Montalban X, Soelberg Sørensen P, Miller DH, 2016 ECTRIMS Focused Workshop Group (2017) Environmental modifiable risk factors for multiple sclerosis: report from the 2016 ECTRIMS focused workshop. Mult Scler 6:1352458516686847

    Google Scholar 

  2. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D (2007) Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148:4687–4694

    CAS  Article  Google Scholar 

  3. Ernst MC, Sinal CJ (2010) Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab 21:660–667

    CAS  Article  Google Scholar 

  4. Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, Mahaney MC, Rainwater DL, VandeBerg JL, MacCluer JW, Collier G, Blangero J, Walder K, Jowett JBM (2009) Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 94(8):3085–3088

    CAS  Article  Google Scholar 

  5. Sell H, Divoux A, Poitou C, Basdevant A, Bouillot JL, Bedossa P, Tordjman J, Eckel J, Clément K (2010) Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 95:2892–2896

    CAS  Article  Google Scholar 

  6. Tomalka-Kochanowska J, Baranowska B, Wolinska-Witort E, Uchman D, Litwiniuk A, Martynska L, Kalisz M, Bik W, Jan Kochanowski J (2014) Plasma chemerin levels in patients with multiple sclerosis. Neuro Endocrinol Lett 35(3):218–223

    CAS  PubMed  Google Scholar 

  7. Owji M, Ashraf-Ganjouei A, Sahraian MA, Bidadian M, Ghadiri F, Naser Moghadasi A (2019) The relationship between cognitive function and body mass index in multiple sclerosis patients. Mult Scler Relat Disord 32:37–40

    Article  Google Scholar 

  8. Briggs FBS, Thompson NR, Conway DS (2019) Prognostic factors of disability in relapsing remitting multiple sclerosis. Mult Scler Relat Disord 30:9–16

    Article  Google Scholar 

  9. Marck CH, Neate SL, Taylor KL, Weiland TJ, Jelinek GA (2016) Prevalence of comorbidities, overweight and obesity in an international sample of people with multiple sclerosis and associations with modifiable lifestyle factors. PLoS One 11(2):e0148573

    Article  Google Scholar 

  10. Tettey P, Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Dwyer T, Kostner K, van der Mei I (2014) An adverse lipid profile is associated with disability and progression in disability, in people with MS. Mult Scler 20(13):1737–1744

    CAS  Article  Google Scholar 

  11. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444

    CAS  Article  Google Scholar 

  12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419

    CAS  Article  Google Scholar 

  13. Ld I-R, Pisarchyk L, Pérez-Luque EL, Garay-Sevilla ME, Malacara JM (2014) Whole-body and hepatic insulin resistance in obese children. PLoS One 9(11):e113576

    Article  Google Scholar 

  14. Dagenais E, Rouleau I, Demers M, Jobin C, Roger E, Chamelian L, Duquette P (2013) Value of the MoCA test as a screening instrument in multiple sclerosis. Can J Neurol Sci 40(3):410–415

    Article  Google Scholar 

  15. Smith A (1991) Symbol digit modalities test. Western Psychological Services, Los Angeles

    Google Scholar 

  16. Deloire MS, Bonnet MC, Salort E, Arimone Y, Boudineau M, Petry KG, Brochet B (2006) How to detect cognitive dysfunction at early stages of multiple sclerosis? Mult Scler 12:445–452

    CAS  Article  Google Scholar 

  17. Sepulcre J, Vanotti S, Hernandez R, Sandoval G, Cáceres F, Garcea O, Villoslada P (2006) Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery Neuropsychology test. Mult Scler 12:187–195

    CAS  Article  Google Scholar 

  18. Parmenter BA, Weinstock-Guttman B, Garg N, Munschauer F, Benedict RHB (2007) Screening for cognitive impairment in multiple sclerosis using the symbol digit modalities test. Mult Scler 13:52–57

    CAS  Article  Google Scholar 

  19. Topolski TD, LoGerfo J, Patrick DL, Williams B, Walwick J, Patrick MB (2006) The rapid assessment of physical activity (RAPA) among older adults. Prev Chronic Dis 3:1–8

    Google Scholar 

  20. Çekok FK, Kahraman T, Kalkışım M, Genç A, Keskinoğlu P (2017) Cross-cultural adaptation and psychometric study of the Turkish version of the rapid assessment of physical activity. Geriatr Gerontol Int 17(11):1837–1842

    Article  Google Scholar 

  21. Minden SL, Feinstein A, Kalb RC, Miller D, Mohr DC, Patten SB, Bever C Jr, Schiffer RB, Gronseth GS, Narayanaswami P (2014) Evidence based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82:174–181

    Article  Google Scholar 

  22. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123

    CAS  Article  Google Scholar 

  23. Armutlu K, Korkmaz N, Keser I, Sumbuloglu V, Akbiyik DI, Guney Z, Karabudak R (2007) The validity and reliability of the Fatigue Severity Scale in Turkish multiple sclerosis patients. Int J Rehabil Res 30:81–85

    Article  Google Scholar 

  24. Hedstrom AK, Lima Bomfim I, Barcellos L, Gianfrancesco M, Schaefer C, Kockum I, Olsson T, Alfredsson L (2014) Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology 82(10):865–872

    Article  Google Scholar 

  25. Lausten-Thomsen U, Christiansen M, Louise Hedley P, Esmann Fonvig C, Stjernholm T, Pedersen O, Hansen T, Holm JC (2016) Reference values for serum leptin in healthy non-obese children and adolescents. Scand J Clin Lab Invest 76(7):561–567

    CAS  Article  Google Scholar 

  26. Gu P, Jiang W, Lu B, Shi Z (2014) Chemerin is associated with inflammatory markers and metabolic syndrome phenotypes in hypertension patients. Clin Exp Hypertens 36:326–332

    CAS  Article  Google Scholar 

  27. Alfadda AA, Sallam RM, Chishti MA, Moustafa AS, Fatma S, Alomaim WS, Al-Naami MY, Bassas AF, Chrousos GP, Jo H (2012) Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: adipose depot specificity and gender dimorphism. Mol Cell 33(6):591–596

    CAS  Article  Google Scholar 

  28. Sledzinski T, Korczynska J, Hallmann A, Kaska L, Proczko-Markuszewska M, Stefaniak T, Sledzinski M, Swierczynski J (2013) The increase of serum chemerin concentration is mainly associated with the increase of body mass index in obese, non-diabetic subjects. J Endocrinol Investig 36(6):428–434

    CAS  Google Scholar 

  29. Munger KL, Chitnis T, Ascherio A (2009) Body size and risk of MS in two cohorts of US women. Neurology 73(19):1543–1550

    Article  Google Scholar 

  30. Munger KL, Bentzen J, Laursen B, Stenager E, Koch-Henriksen N, Sørensen TI, Baker JL (2013) Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult Scler 19(10):1323–1329

    Article  Google Scholar 

  31. Weinstock-Guttman B, Zivadinov R, Mahfooz N, Carl E, Drake A, Schneider J, Teter B, Hussein S, Mehta B, Weiskopf M, Durfee J, Bergsland N, Ramanathan M (2011) Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation 8:127

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Neurology, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Saim Cikrikci cad. No:59 Karabaglar, 35170, Izmir, Turkey

    Asli Koskderelioglu, Muhtesem Gedizlioglu, Neslihan Eskut & Pinar Tamer

  2. Department of Biochemistry, University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey

    Gizem Yalcin & Giray Bozkaya

Authors
  1. Asli Koskderelioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Muhtesem Gedizlioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neslihan Eskut
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pinar Tamer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gizem Yalcin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giray Bozkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Asli Koskderelioglu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The present study was performed under the ethical standards of the 1964 Declaration of Helsinki and its later amendments. The Ethical Committee of the University of Health Sciences, Bozyaka Education and Research Hospital approved the study protocol (Ethical approval license: Reference Number: 04, Date 16.05.2018). Informed consent was obtained from all individuals who participated in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Koskderelioglu, A., Gedizlioglu, M., Eskut, N. et al. Impact of chemerin, lipid profile, and insulin resistance on disease parameters in patients with multiple sclerosis. Neurol Sci 42, 2471–2479 (2021). https://doi.org/10.1007/s10072-020-04847-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-020-04847-y

Keywords

  • Multiple sclerosis
  • Disease activity
  • Chemerin
  • Obesity